MedTrace Logo

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

NCT05524935 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-04-01

No results posted yet for this study

Summary

This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab Day 1 of each 21 day (3 week) cycle

DRUG

Olaparib

Olaparib by mouth days 1-21 of each 21 day (3 week) cycle

Sponsors & Collaborators

Principal Investigators

  • Nikhil I Khushalani, MD · Moffitt Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05524935 on ClinicalTrials.gov